Amgen Inc. (AMGN)
Amgen gains after strong quarterly results and continued product momentum
Amgen Inc (NASDAQ:AMGN, XETRA:AMG) shares rose about 4% on Wednesday after the biotechnology company reported second quarter 2026 results that topped Wall Street expectations, supported by higher revenue and growth across its portfolio of medicines. The company reported adjusted earnings per share of $6.29 for the quarter, ahead of analyst estimates of roughly $5.60 to $5.62.
AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.
AMGN Q2 Earnings Call Centers on Raised Outlook and Pipeline
Amgen raised its 2026 outlook as broad product growth funds a deeper late-stage pipeline push amid biosimilar pressure on older franchises.
Amgen Inc. (AMGN) Q2 2026 Earnings Call Transcript
Amgen Inc. (AMGN) Q2 2026 Earnings Call Transcript
Amgen (AMGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) Q2 Earnings and Revenues Surpass Estimates
Amgen (AMGN) came out with quarterly earnings of $6.29 per share, beating the Zacks Consensus Estimate of $5.6 per share. This compares to earnings of $6.02 per share a year ago.
Amgen Q2 Earnings Call Highlights
Amgen NASDAQ: AMGN reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spending on late-stage clinical programs and manufacturing capacity.
Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment
The biotechnology company now expects full-year revenue between $38.2 billion and $39.4 billion, but said it was halting the development of a potential obesity treatment currently in a phase 1 study.
Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
The second-quarter 2026 reporting cycle of the Medical sector is currently in full swing. The sector mainly comprises pharma/biotech and medical device companies.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Amgen Q2 Earnings Preview: Will the Beat Streak Continue?
Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.
What Analyst Projections for Key Metrics Reveal About Amgen (AMGN) Q2 Earnings
Besides Wall Street's top-and-bottom-line estimates for Amgen (AMGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
